NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Powers BJ, Crowley MJ, McCrory DC, et al. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension: Identification of Future Research Needs From Comparative Effectiveness Review No. 34 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Mar. (Future Research Needs Papers, No. 14.)

Cover of Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension

Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension: Identification of Future Research Needs From Comparative Effectiveness Review No. 34 [Internet].

Show details

Appendix AExact Search Strings

The exact search strings used for this project are given below.

MEDLINE® via Ovid (update of search done for original CER)

Search date: November 14, 2011

SetTermsResults
1(losartan or valsartan or telmisartan or eprosartan or candesartan or irbesartan or olmesartan).mp.12976
2losartan/5301
3exp angiotensin II type 1 receptor blockers/ or exp Receptors, Angiotensin/ai [Antagonists & Inhibitors]11741
4(cozaar or micardis or atacand or tevetan or avapro or benicar or diovan).mp.130
5or/1-416740
6(quinapril or perindopril or ramipril or captopril or enalapril or benazepril or trandolapril or fosinopril or moexipril or enalaprilat or cilazapril or saralasin or teprotide).mp.25618
7angiotensin-converting enzyme inhibitors/ or captopril/ or cliazapril/ or enalapril/ or enalaprilat/ or fosinopril/ or lisinopril/ or perindopril/ or ramipril/ or saralasin/ or teprotide/37922
86 or 741516
95 and 86538
10limit 9 to yr=“2010 - current”544
11limit 10 to english language496
12exp hypertension/dt53251
1311 and 12128
14randomized controlled trial.pt.321519
15controlled clinical trial.pt.83947
16Randomized Controlled Trials/77891
17Random Allocation/73587
18Double-Blind Method/113895
19Single-Blind Method/15743
20or/14-19540647
21Animal/ not Human/3621311
2220 not 21500390
23clinical trial.pt.469975
24exp Clinical Trial/667855
25(clinic$ adj25 trial$).tw.201771
26((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.111399
27Placebos/30695
28placebo$.tw.134423
29random$.tw.544924
30Research Design/65156
31(Latin adj square).tw.2982
32or/23-311152741
3332 not 211062417
34Comparative Study/1567956
35exp Evaluation Studies/160340
36Follow-up Studies/437364
37Prospective Studies/310272
38(control$ or prospectiv$ or volunteer$).tw.2455249
39Cross-Over Studies/29081
40or/34-394117015
4140 not 213181350
4222 or 33 or 413671587
4313 and 4270
44limit 43 to abstracts67
45(aliskiren or tekturna).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]523
46(renin inhibitor or renin inhibitors).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]1099
47renin/ai1507
48or/45-471913
495 and 48311
5049 and 42 and 1278
518 and 48545
5251 and 42 and 1294
5350 or 52123
54limit 53 to english language110
5543 or 54167

PubMed® via Ovid (search for systematic reviews)

Search date: December 16, 2011

Set #TermsResults
#1((“losartan”[MeSH Terms] OR “losartan”[tw]) OR (“valsartan”[Supplementary Concept] OR “valsartan”[tw]) OR (“telmisartan”[Supplementary Concept] OR “telmisartan”[tw]) OR (“eprosartan”[Supplementary Concept] OR “eprosartan”[tw]) OR (“candesartan”[Supplementary Concept] OR “candesartan”[tw]) OR (“irbesartan”[Supplementary Concept] OR “irbesartan”[tw]) OR (“olmesartan”[Supplementary Concept] OR “olmesartan”[tw]) OR (“angiotensin ii type 1 receptor blockers”[MeSH Terms] OR “angiotensin ii type 1 receptor blockers”[tw] OR “angiotensin ii type 1 receptor blockers”[Pharmacological Action]) OR (“losartan”[MeSH Terms] OR “losartan”[tw] OR “cozaar”[tw]) OR (“telmisartan”[Supplementary Concept] OR “telmisartan”[tw] OR “micardis”[tw]) OR (“candesartan cilexetil”[Supplementary Concept] OR “candesartan cilexetil”[tw] OR “atacand”[tw]) OR (“eprosartan”[Supplementary Concept] OR “eprosartan”[tw] OR “teveten”[tw]) OR (“irbesartan”[Supplementary Concept] OR “irbesartan”[tw] OR “avapro”[tw]) OR (“olmesartan medoxomil”[Supplementary Concept] OR “olmesartan medoxomil”[tw] OR “benicar”[tw]) OR (“valsartan”[Supplementary Concept] OR “valsartan”[tw] OR “diovan”[tw])16858
#2(“quinapril”[Supplementary Concept] OR “quinapril”[tw]) OR (“perindopril”[MeSH Terms] OR “perindopril”[tw]) OR (“ramipril”[MeSH Terms] OR “ramipril”[tw]) OR (“captopril”[MeSH Terms] OR “captopril”[tw]) OR (“enalapril”[MeSH Terms] OR “enalapril”[tw]) OR (“benazepril”[Supplementary Concept] OR “benazepril”[tw]) OR (“trandolapril”[Supplementary Concept] OR “trandolapril”[tw]) OR (“fosinopril”[MeSH Terms] OR “fosinopril”[tw]) OR (“moexipril”[Supplementary Concept] OR “moexipril”[tw]) OR (“enalaprilat”[MeSH Terms] OR “enalaprilat”[tw]) OR (“cilazapril”[MeSH Terms] OR “cilazapril”[tw]) OR (“saralasin”[MeSH Terms] OR “saralasin”[tw]) OR (“teprotide”[MeSH Terms] OR “teprotide”[tw]) OR (“angiotensin-converting enzyme inhibitors”[MeSH Terms] OR (“angiotensin-converting”[tw] AND “enzyme”[tw] AND “inhibitors”[tw]) OR “angiotensin-converting enzyme inhibitors”[tw] OR (“angiotensin”[tw] AND “converting”[tw] AND “enzyme”[tw] AND “inhibitors”[tw]) OR “angiotensin converting enzyme inhibitors”[tw] OR “angiotensin-converting enzyme inhibitors”[Pharmacological Action]) OR (“captopril”[MeSH Terms] OR “captopril”[tw]) OR (“cilazapril”[MeSH Terms] OR “cilazapril”[tw]) OR (“enalapril”[MeSH Terms] OR “enalapril”[tw]) OR (“enalaprilat”[MeSH Terms] OR “enalaprilat”[tw]) OR (“fosinopril”[MeSH Terms] OR “fosinopril”[tw]) OR (“lisinopril”[MeSH Terms] OR “lisinopril”[tw]) OR (“perindopril”[MeSH Terms] OR “perindopril”[tw]) OR (“ramipril”[MeSH Terms] OR “ramipril”[tw]) OR (“saralasin”[MeSH Terms] OR “saralasin”[tw]) OR (“teprotide”[MeSH Terms] OR “teprotide”[tw])47412
#3OR (“aliskiren”[Supplementary Concept] OR “aliskiren”[tw]) OR (“aliskiren”[Supplementary Concept] OR “aliskiren”[tw] OR “tekturna”[tw]) OR ((“renin”[MeSH Terms] OR “renin”[tw]) AND inhibitor[tw]) OR ((“renin”[MeSH Terms] OR “renin”[All Fields]) AND (“antagonists and inhibitors”[Subheading] OR (“antagonists”[tw] AND “inhibitors”[tw]) OR “antagonists and inhibitors”[tw] OR “inhibitors”[tw]))) OR (“Angiotensin-Converting Enzyme Inhibitors”[Mesh] OR “Angiotensin-Converting Enzyme Inhibitors”[Pharmacological Action]) OR (“Angiotensin Receptor Antagonists”[Mesh] OR “Angiotensin Receptor Antagonists”[Pharmacological Action] OR “Angiotensin II Type 2 Receptor Blockers”[Mesh] OR “Angiotensin II Type 1 Receptor Blockers”[Mesh]) OR “Renin/antagonists and inhibitors”[Mesh] OR “direct renin inhibitors”[tw] OR “DRI”[tw] OR “DRIs”[tw]53191
#4AND (English[lang] AND systematic[sb] NOT (“infant”[MeSH Terms] OR (“infant”[MeSH Terms] OR “child”[MeSH Terms] OR “adolescent”[MeSH Terms] OR (“animals”[MeSH Terms:noexp])) AND (“2008”[PDAT] : “2011”[PDAT])) AND English[lang] AND systematic[sb] AND (“2008”[PDAT] : “2011”[PDAT]))51550
#5(#1 OR #2 OR #3) AND#4356
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (597K)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...